Jul 18, 2025
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
Jun 26, 2025
Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
Jun 12, 2025
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025
Jun 02, 2025
Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
May 08, 2025
Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook
May 08, 2025
Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
May 07, 2025
Viatris Announces Quarterly Dividend
May 05, 2025
Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
Apr 25, 2025
Viatris to Present at the BofA Securities 2025 Healthcare Conference
Apr 21, 2025
Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder
Apr 14, 2025
Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer
Apr 07, 2025
Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims
Mar 28, 2025
Viatris to Report First Quarter 2025 Financial Results on May 8, 2025
Feb 27, 2025
Viatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend
Feb 27, 2025
Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance
Feb 03, 2025
Viatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Jan 07, 2025
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 18, 2024
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology
Nov 07, 2024
Viatris Reports Third Quarter Financial Results for 2024
Nov 05, 2024
Viatris Announces Third Quarter 2024 Dividend